

1. DAI MEDICO

UNITA' COMPLESSA DI GASTROENTEROLOGIA

Principal Investigator: Prof Salvatore Petta

1: Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group.

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

N Engl J Med. 2025 Jun 5;392(21):2089-2099.

Impact Factor 2024: 78.5

2: Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ; SYNERGY-NASH Investigators.

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

N Engl J Med. 2024 Jul 25;391(4):299-310.

Impact Factor 2024: 78.5

3: Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Nouredin M, Alkhouri N, Younes R; 1404-0043 Trial Investigators.

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

N Engl J Med. 2024 Jul 25;391(4):311-319.

Impact Factor 2024: 78.5

Principal Investigator: Prof.ssa Vincenza Calvaruso

1: Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU, Cobitz AR, Currie BM, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon JB, Swift B, McLaughlin MM, Levy C; GLISTEN Study Group.

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Lancet Gastroenterol Hepatol. 2026 Jan;11(1):22-33.

Impact Factor 2024: 38.6

2: Pompili E, Baldassarre M, Iannone G, Tedesco G, Nardelli S, Piano S, Alessandria C, Neri S, Foschi FG, Levantesi F, Caraceni P, Bernardi M, Zaccherini G; ANSWER Study Investigators.

Long-term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial.

Liver Int. 2024 Sep;44(9):2108-2113.

Impact Factor 2024: 5.2

3: Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladrón de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado MC, Berghceanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; RESPONSE Study Group.

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.

N Engl J Med. 2024 Feb 29;390(9):783-794.

Impact Factor 2024: 78.5

4: Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM;

ELATIVE Study Investigators' Group;

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

N Engl J Med. 2024 Feb 29;390(9):795-805.

Impact Factor 2024: 78.5

Principal Investigator: Prof. Giuseppe Cabibbo

1: Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiattkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.

Lancet Oncol. 2023 Dec;24(12):1399-1410.

Impact Factor 2024: 35.9

2: Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A.

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.

Eur J Cancer. 2023 Feb;180:9-20.

Impact Factor 2024: 11.4

PROGRAMMA SEMPLICE DIPARTIMENTALE DI NUTRIZIONE, OBESITA' E METABOLISMO

Principal investigator: Prof Silvio Buscemi

1: Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, Plutzky J, Kushner RF, Colhoun HM, Hovingh GK, Stensen S, Weeke PE, Jeppesen OK, Bravo R, Wu CC, Komuro I, Santini F, Hjelmæsæth J, Urina-Triana M, Buscemi S, Ryan DH.

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.

Lancet. 2025 Nov 8;406(10516):2257-2268

Impact Factor 2024: 88.5

2: McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelman MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB;

SOUL Study Group.

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

N Engl J Med. 2025 May 29;392(20):2001-2012.

Impact Factor 2024: 78.5

3: Scirica BM, Lincoff AM, Lingvay I, Bogdanski P, Buscemi S, Colhoun H, Craciun AE, Ezhov M, Hardt-Lindberg S, Kleist Jeppesen O, Matos ALSA, Node K, Schiele F, Toplak H, van Beek A, Weeke PE, Wiviott SD, Deanfield J, Ryan D.

The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.

J Am Coll Cardiol. 2024 Oct 22;84(17):1632-1642.

Impact Factor 2024: 22.3

4: Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM;
SELECT Trial Investigators.

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.

Lancet. 2024 Aug 24;404(10454):773-786.

Impact Factor 2024: 88.5

5: Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH;
SELECT Trial Investigators.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

N Engl J Med. 2023 Dec 14;389(24):2221-2232.

Impact Factor 2024: 78.5

6: Rosenstock J, Bain SC, Gowda A, Jódar E, Liang B, Lingvay I, Nishida T, Trevisan R, Mosenzon O;
ONWARDS 1 Trial Investigators.

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.

N Engl J Med. 2023 Jul 27;389(4):297-308.

Impact Factor 2024: 78.5

7: Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Garvey WT.

Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.

Obesity (Silver Spring). 2023 Mar;31(3):703-715.

Impact Factor 2024: 4.7

UNITA' COMPLESSA DI MEDICINA INTERNA E GERIATRIA

Principal Investigator: Prof Mario Barbagallo

1: Veronese N, Fazzari A, Santangelo E, Iommi C, Soysal P, Custodero C, Pickert L, Polidori MC, Stolniceanu N, Michalkova H, Topinkova E, Pilotto A, Barbagallo M.

The role of comprehensive geriatric assessment in older patients affected by knee osteoarthritis: an exploratory randomized controlled trial.

Aging Clin Exp Res. 2025 May 16;37(1):155.

Impact Factor 2024: 3.4

2: Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS;
GRADUATE I and II Investigators and the Gantenerumab Study Group.

Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.

N Engl J Med. 2023 Nov 16;389(20):1862-1876.

Impact Factor 2024: 78.5

Principal Investigator: Prof Pasquale Mansueto

1: Lungaro L, Malfa P, Manza F, Negrelli M, Costanzini A, Squarzanti DF, Lo Re M, Cariani A, Ghisellini S, Caputo F, De Giorgi A, Mansueto P, Carroccio A, De Giorgio R, Caio G. Clinical Efficacy of Probiotics for Relieving Cold Symptoms in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Nutrients. 2025 Apr 28;17(9):1490.

Impact Factor 2024: 5.0

UNITA' OPERATIVA COMPLESSA DI PNEUMOLOGIA

Principal Investigator: Prof Nicola Scichilone

1: Papi A, Forini G, Maniscalco M, Bargagli E, Crimi C, Santus P, Molino A, Bandiera V, Baraldi F, D'Anna SE, Carone M, Marvisi M, Pelaia C, Scioscia G, Patella V, Aliani M, Fabbri LM; ICSLIFE Study Group.

Long-term inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease, cardiovascular disease, and a recent hospitalised exacerbation: The ICSLIFE pragmatic, randomised controlled study.

Eur J Intern Med. 2024 Oct;128:104-111.

Impact Factor 2024: 6.1

Principal Investigator: Prof Salvatore Battaglia

1: Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasí F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML;

ASPEN Investigators.

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.

N Engl J Med. 2025 Apr 24;392(16):1569-1581.

Impact Factor 2024: 78.5

Principal Investigator: Prof.ssa Alida Benfante

1: Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Luíz Martinez G, Dymek L, Jacques L, Bird N, Schalkwijk S, Smith D, Howarth P, Pavord ID; SWIFT-1 and SWIFT-2 Investigators; SWIFT-1 Investigators; SWIFT-2 Investigators. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.

N Engl J Med. 2024 Dec 19;391(24):2337-2349

Impact Factor 2024: 78.5

UNITA' COMPLESSA DI MALATTIE ENDOCRINE DEL RICAMBIO E DELLA NUTRIZIONE

Principal Investigator: Prof.ssa Carla Giordano

1: Rossing P, Bakris G, Perkovic V, Pratley R, Tuttle KR, Mahaffey KW, Idorn T, Belmar N, Bosch-Traberg H, Rasmussen S, Busch RS, Schmieder RE, Gillard P, Mann JFE; FLOW Investigator Group.

Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.

Diabetes Care. 2025 Nov 1;48(11):1878-1887.

Impact Factor 2024: 16.6

2: Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R;

FLOW Trial Committees and Investigators.

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

N Engl J Med. 2024 Jul 11;391(2):109-121.

Impact Factor 2024: 78.5

2. DAI EMERGENZA -URGENZA

UNITA' OPERATIVA COMPLESSA DI TERAPIA INTENSIVA

Principal Investigator: Prof Andrea Cortegiani

1: Azoulay É, Myatra SN, Heras La Calle G, Jaber S, Boulanger C, Demirkýran O, Theodorakopoulou M, Paiva JA, Arabi YM, Burghi G, van Heerden PV, Al Fares A, Kentish-Barnes N, Martin-Delgado MC, Mistraletti G, Francois G, Barth A, De Waele J, Shanafelt TD, Darmon M, Cecconi M;

European Society of Intensive Care Medicine.

Positive communication for decreasing burnout in intensive-care-unit staff: a cluster-randomized trial.

Intensive Care Med. 2025 Nov;51(11):2031-2041.
Impact Factor 2024: 22.5

2: ANDROMEDA-SHOCK-2 Investigators for the ANDROMEDA Research Network, Spanish Society of Anesthesiology, Reanimation and Pain Therapy (SEDAR), and Latin American Intensive Care Network (LIVEN); Hernandez G, Ospina-Tascón GA, Kattan E, Ibarra-Estrada M, Ramasco F, Orozco N, Ramos K, Aldana JL, Ferri G, Hamzaoui O, De Backer D, Teboul JL, Vieillard-Baron A, Petri Damiani L, García-Gallardo GA, Morales S, Carmona Garcia P, Mendez R, Hernandez-Gilsoul T, Pérez-Nieto OR, Olea Vielba C, Ramos S, Dominguez D, Bruna M, David S, Wendel-Garcia PD, Galiana-Ivars M, Myatra SN, Messina A, Cecconi M, Pozo M, Amthauer M, Higuera E, Al Duhalib Z, Rico-Feijoo J, Ferrer-Gómez C, Pérez-Carbonell A, Martínez-Castro S, Redondo Calvo FJ, Vives M, Sanchez HF, Bilbao I, Fernandez P, Al-Fares A, Benítez-Cano A, Gonzalez C, Reyes LF, Rodríguez-Guillen JH, Cristino AV, Pendino JC, Ortiz G, Alonso-Gonzalez MC, Murias G, Aguirre-Avalos G, Hernández L, Calderón Barajas ZA, Zarragoikoetxea I, Monnet X, Goury A, Mendonça Dos Santos T, Vallecilla L, Martins de Lima L, Sady E, Alegria L, Ostermann M, Bakker J, Biasi Cavalcanti A.

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial.

JAMA. 2025 Dec 9;334(22):1988-1999.

Impact Factor 2024: 55.5

3: Nasa P, van Meenen DMP, Paulus F, Ferrando C, Bluth T, Gama de Abreu M, Ball L, Bossers SM, Schober P, Schultz MJ, Serpa Neto A, Hemmes SNT;

REPEAT; PROVHILO; PROBESE; investigators of the PROVE network; ESAIC CTN.

Association of intraoperative end-tidal CO levels with postoperative outcomes: a patient-level analysis of two randomised clinical trials.

Br J Anaesth. 2025 Dec;135(6):1761-1769.

Impact Factor 2024: 9.2

4: Pontillo D, Rong LQ, Pruna A, Pisano A, Monaco F, Bruni A, Baiardo Redaelli M, Ti LK, Belletti A, Bradic N, Massaro C, Barucco G, Viscido C, Losiggio R, Federici F, Marmiere M, Silvetti S, Marchetti C, Carmosino M, Manazza M, Oliva FM, Cortegiani A, Guarracino F, Ranucci M, Paternoster G, Landoni G, Zangrillo A, Gaudino MFL, Bellomo R;

PROTECTION Study Group Collaborators.

Impact of Cardiopulmonary Bypass Duration on the Renal Effects of Amino Acids Infusion in Cardiac Surgery Patients.

J Cardiothorac Vasc Anesth. 2025 Sep;39(9):2296-2306.

Impact Factor 2024: 2.1

5: Baiardo Redaelli M, Monaco F, Bradic N, Scandroglio AM, Ti LK, Belletti A, Viscido C, Licheri M, Guarracino F, Pruna A, Pisano A, Pontillo D, Federici F, Losiggio R, Serena G, Tomasi E, Silvetti S, Ranucci M, Brazzi L, Cortegiani A, Landoni G, Mastroberto P, Paternoster G, Gaudino MFL, Zangrillo A, Bellomo R; for the PROTECTION Study Group Collaborators.

Amino Acid Infusion for Kidney Protection in Cardiac Surgery Patients with Chronic Kidney Disease: A Secondary Analysis of the PROTECTION Trial.

Anesthesiology. 2025 May 1;142(5):818-828.

Impact Factor 2024: 9.3

6: Landoni G, Monaco F, Ti LK, Baiardo Redaelli M, Bradic N, Comis M, Kotani Y, Brambillasca C, Garofalo E, Scandroglio AM, Viscido C, Paternoster G, Franco A, Porta S, Ferrod F, Calabrò MG, Pisano A, Vendramin I, Barucco G, Federici F, Severi L, Belletti A, Cortegiani A, Bruni A, Galbiati C, Covino A, Baryshnikova E, Giardina G, Venditto M, Kroeller D, Nakhnoukh C, Mantovani L, Silvetti S, Licheri M, Guarracino F, Lobreglio R, Di Prima AL, Fresilli S, Labanca R, Mucchetti M, Lembo R, Losiggio R, Bove T, Ranucci M, Fominskiy E, Longhini F, Zangrillo A, Bellomo R;

PROTECTION Study Group.

A Randomized Trial of Intravenous Amino Acids for Kidney Protection.

N Engl J Med. 2024 Aug 22;391(8):687-698.

Impact Factor 2024: 78.5

7: Vaschetto R, Gregoretti C, Scotti L, De Vita N, Carlucci A, Cortegiani A, Crimi C, Mattei A, Scala R, Rocca E, Longhini F, Cammarota G, Misseri G, Dal Molin A, Scolletta S, Nava S, Maggiore SM, Navalesi P.

A pragmatic, open-label, multi-center, randomized controlled clinical trial on the rotational use of interfaces vs standard of care in patients treated with noninvasive positive pressure ventilation for acute hypercapnic respiratory failure: the ROTational-USE of interface STUDY (ROTA-USE STUDY).

Trials. 2023 Aug 13;24(1):527.

Impact Factor 2024: 2.0

8: Crimi C, Noto A, Madotto F, Ippolito M, Nolasco S, Campisi R, De Vuono S, Fiorentino G, Pantazopoulos I, Chalkias A, Libra A, Mattei A, Scala R, Clini EM, Ergon B, Lujan M, Winck JC, Giarratano A, Carlucci A, Gregoret C, Groff P, Cortegiani A; COVID-HIGH Investigators.

High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial.

Thorax. 2023 Apr;78(4):354-361.

Impact Factor 2024: 10.8

UNITA' OPERATIVA COMPLESSA DI CARDIOLOGIA

Principal Investigator: Prof.ssa Giuseppina Novo

1: Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebac J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA; AEGIS-II Committees and Investigators.

Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.

N Engl J Med. 2024 May 2;390(17):1560-1571.

Impact Factor 2024: 78.5

UNITA' OPERATIVA COMPLESSA ASTANTERIA/MCAU

Principal investigator: Prof. Angelo Baldassare Cefalù

1: Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimmerman A, Moura FA, Kang YM, Weinland J, Murphy SA, Goodrich EL, Zhang S, Li D, Banach M, Stroes E, Lu MT, Tsimikas S, Giugliano RP, Sabatine MS;

Essence-TIMI 73b Investigators.

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.

N Engl J Med. 2025 Oct 2;393(13):1279-1291.

Impact Factor 2024: 78.5

UNITA' OPERATIVA COMPLESSA DI MALATTIE INFETTIVE E TROPICALI

Principal Investigator : Prof Antonio Cascio

1: Mastrorosa I, Cozzi-Lepri A, Matusali G, Colavita F, Lanini S, Rueca M, Oliva A, Berno G, Vergori A, Rosati S, Paulicelli J, Girardi E, Nicastri E, Maggi F, Antinori A, Mazzotta V; MONET Clinical Trial Group.

CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease.

Sci Rep. 2025 Aug 18;15(1):30244.

Impact Factor 2024: 3.9.

2: Capone S, Fusco FM, Milleri S, Borrè S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannaccone C, Carsetti R, Folgori A, Camerini R;

COVITAR study group.

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.

Cell Rep Med. 2023 Jun 20;4(6):101084.

Impact Factor 2024: 10.6

3. DAI RADIOLOGIA DIAGNOSTICA, INTERVENTISTICA E STROKE

UNITA' OPERATIVA COMPLESSA DI NEUROLOGIA

Principal Investigator: Prof Giuseppe Salemi

1: Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators.

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

Lancet Neurol. 2024Nov;23(11):1119-1132.

Impact Factor 2024: 45.5

2: Amato A, Proia P, Alioto A, Rossi C, Pagliaro A, Ragonese P, Schirò G, Salemi G, Caldarella R, Vasto S, Nowak R, Kostrzewa-Nowak D, Musumeci G, Baldassano S.

High-intensity interval training improves bone remodeling, lipid profile, and physical function in multiple sclerosis patients.

Sci Rep. 2024 Jul 13;14(1):16195.

Impact Factor 2024: 3.9

4. DAI DI ONCOLOGIA E SANITA' PUBBLICA

UNITA' OPERTIVA COMPLESSA DI ONCOLOGIA

Principal Investigator: Prof Antonio Russo

1: Marchetti P, Curigliano G, Biffoni M, Lonardi S, Scagnoli S, Fornaro L, Guarneri V, De Giorgi U, Ascierto PA, Blandino G, D'Amati G, Aglietta M, Cremolini C, Conte P, Crimini E, Ceracchi M, Pisegna S, Verkhovskaia S, Bordonaro R, Bracarda S, Butturini G, Del Mastro L, DeCensi A, Fabbri A, Fenocchio E, Gori S, Metro G, Pessino A, Pozzessere D, Puglisi F, Tamberi S, Zambelli A, Marino D, Capoluongo E, Cappuzzo F, Cerbelli B, Giannini G, Malpele U, Mazzuca F, Nuti M, Prunerì G, Simmaco M, Strigari L, Tonini G, Martini N, Botticelli A;

ROME trial investigators consortia.

Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.

Nat Med. 2025 Oct;31(10):3514-3523.

Impact Factor 2024: 50

2: Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti MG, Aieta M, Ciccarese M, Pisconti S, Bordonaro R, Russo A, Febbraro A, Schiavone P, Quaranta A, Caliolo C, Loparco D, Cinefra M, Colucci G, Cinieri S;

Gruppo Oncologico dell'Italia Meridionale (GOIM).

Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.

Breast. 2024 Jun;75:103725. doi:

Impact Factor 2024: 7.9

3: Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenzov Y, Wu YL; ADAURA Investigators.

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

N Engl J Med. 2023 Jul13;389(2):137-147.
Impact Factor 2024: 78.5

Principal Investigator: Prof Giuseppe Badalamenti

1: Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, Gelsomino F, Brizzi MP, Di Meglio G, Spada F, Tamberi S, Lolli I, Cives M, Marconcini R, Pucci F, Berardi R, Antonuzzo L, Badalamenti G, Santini D, Recine F, Vanni S, Tebaldi M, Severi S, Rudnas B, Nanni O, Ranallo N, Crudi L, Calabrò L, Ibrahim T. A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.
Eur J Cancer. 2024 Sep;208:114129.
Impact Factor 2024: 7.1

UNITA' OPERATIVA COMPLESSA DI EMATOLOGIA

Principal Investigator Prof. Sergio Siragusa

1: Sartori M, Iotti M, Camporese G, Siragusa S, Imberti D, Bucherini E, Corradini S, Ageno W, Prandoni P, Ghirarduzzi A.
Six-week low-molecular-weight eparine versus 12-week warfarin for calf deep vein thrombosis: A randomized, prospective, open-label study.
Am J Hematol. 2024 May;99(5):854-861.
Impact Factor 2024: 12.8

2: Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
NEJM Evid. 2023 Jun;2(6):EVIDoa2200335.
Impact Factor 2024: 78.5

3: Mazzucconi MG, Rodeghiero F, Avvisati G, De Stefano V, Gugliotta L, Ruggeri M, Vianelli N, Fazi P, Paoloni F, Sargentini V, Baldacci E, Ferretti A, Martino B, Vincelli ID, Carli G, Fortuna S, Di Ianni M, Ranalli P, Palandri F, Polverelli N, Lugli E, Rivolti E, Patriarca A, Rago A, D'Adda M, Gentile M, Siragusa S, Sibilla S, Carella AM, Rossi E, Battistini R, Zaja F, Bocchia M, Di Renzo N, Musto P, Crugnola M, Giuffrida AC, Krampera M, Tafuri A, Santoro C.
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.
Blood Adv. 2024 Mar 26;8(6):1529-1540.
Impact Factor 2024: 7.1

4: Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol. 2024
Impact Factor 2024: 2.4

Principal Investigator: Prof.ssa Salvatrice Mancuso

1: Novo M, Frascione PMM, Castellino A, Marcheselli L, Dattoli SD, Vannucchi M, Rota-Scalabrini D, Tucci A, Gini G, Tarantini G, Mannina D, Arcari A, Liso A, Scarpa E, Marino D, Spina M, Gorgone A, Di Renzo N, Mancuso S, Petrucci L, Tafuri A, Botto B, Bonello F, Santambrogio E, Vitolo U.
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).
Br J Haematol. 2025 Aug;207(2):445-454.

Impact Factor 2024: 3.9

2: Durmo R, Chauvie S, Minoia C, Bergesio F, Fallanca F, Peano S, Marcheselli L, Anastasia A, Boccomini C, Corradini P, Olivieri J, Arcaini L, Cavallo F, Ibatci A, Nassi L, Tarantino V, Pinto A, Stelitano C, Pulsoni A, Ricci F, Mancuso S, Cencini E, Di Renzo N, Mannarella C, Palmas A, Zinzani P, Bocci C, Rossi F, Carella AM, Federico M, Versari A, Guerra L, Luminari S.

Total Metabolic Tumor

Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas:

Results From a Sub-Study of the FOLL12 Trial.

Am J Hematol. 2025 Jul;100(7):1196-1204.

Impact Factor 2024: 12.8

3: Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Haematologica. 2024 Jul 1;109(7):2297-2302.

Impact Factor 2024: 7.9

UNITA' OPERATIVA COMPLESSA DI EPIDEMIOLOGIA CON REGISTRO TUMORI

Principal Investigator: Prof Francesco Vitale

1: Monti G, Carta S, Kotani Y, Bruni A, Konkayeva M, Guarracino F, Yakovlev A, Cucciolini G, Shemetova M, Scapol S, Momesso E, Garofalo E, Brizzi G, Baldassarri R, Ajello S, Isirdi A, Meroi F, Baiardo Redaelli M, Boffa N, Votta CD, Borghi G, Montrucchio G, Rauch S, D'Amico F, Pace MC, Paternoster G, Vitale F, Giardina G, Labanca R, Lembo R, Marmiere M, Marzaroli M, Nakhnoukh C, Plumari V, Scandroglio AM, Scquizzato T, Sordoni S, Valsecchi D, Agrò FE, Finco G, Bove T, Corradi F, Likhvantsev V, Longhini F, Konkayev A, Landoni G, Bellomo R, Zangrillo A; PPI-SEPSIS Study Group.

A Multinational Randomized Trial of Mega- Dose Esomeprazole as Anti-Inflammatory Agent in Sepsis.

Crit Care Med. 2025 Aug 1;53(8):e1554-e1566.

Impact Factor 2024: 6.0

2: Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Cuadripani S, Deraedt Q, Dezutter N, Gerard C, Fissette L, Xavier S, David MP, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus

seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.

Lancet Respir Med. 2025 Jun;13(6):517-529.

Impact Factor 2024: 32.8

3: Curran D, Matthews S, Cabrera ES, Pérez SN, Brevia LP, Rămet M, Helman L, Park DW, Schwarz TF, Melendez IMG, Schaefer A, Roy N, Stephan B, Molnar D, Kostanyan L, Powers JH 3rd, Hulstrøm V; Membri of the AReSVi-006 Study Group.

The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.

Influenza Other Respir Viruses. 2024 Feb 3;18(2):e13236.

Impact Factor 2024: 4.2

4: Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 Study Group.

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.

Clin Infect Dis. 2024 Jun 14;78(6):1732-1744.
Impact Factor 2024: 7.3

5: Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group.

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

N Engl J Med. 2023 Feb 16;388(7):595-608.

Impact Factor 2024: 78.5

Principial Investigator: Prof Claudio Costantino

1: Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, Grijalva CG, Orenstein WA, Fernsler D, Gallagher N, Zeng T, Li J, Platt HL; STRIDE-6 Study Group. A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6).

Clin Infect Dis. 2024 Dec 17;79(6):1366-1374.

Impact Factor 2024: 7.3

5. DAI RIABILITAZIONE, FRAGILITA' E CONTINUITA' ASSISTENZIALE

UNITA' OPERATIVA COMPLESSA RECUPERO E RIABILITAZIONE FUNZIONALE

Principal Investigatore: Prof.ssa Giulia Letizia Mauro

1: Scaturro D, Vitagliani F, Tomasello S, Sconza C, Respizzi S, Letizia Mauro G. Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferol in Discogenic Sciatica in Young People: A Randomized Clinical Trial.

Medicina (Kaunas). 2023 Dec 18;59(12):2197.

Impact Factor 2024: 2.4

UNITA' OPERATIVA SEMPLICE DIPARTIMENTALE DI MEDICINA ORALE CON ODONTOIATRIA PER PAZIENTI FRAGILI

Principal investigator: Prof.ssa Giuseppina Campisi

1: Di Fede O, La Mantia G, Del Gaizo C, Mauceri R, Matranga D, Campisi G. Reduction of MRONJ risk after exodontia by virtue of ozone infiltration: A randomized clinical trial.

Oral Dis. 2024 Nov;30(8):5183-5194.

Impact Factor 2024: 2.9

2: Bazzano M, Mauceri R, Marcon G, Campisi G.

Reducing the anxiety of patients undergoing an oral biopsy by means of graphic novels: an open-label randomized clinical trial.

Med Oral Patol Oral Cir Bucal. 2023 Nov 1;28(6):e545-e552.

Impact Factor 2024: 2.2